<DOC>
	<DOC>NCT00366704</DOC>
	<brief_summary>The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.</brief_summary>
	<brief_title>Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Inclusion criteria: Current treatment of at least 3 months with risperidone. Primary diagnosis of schizophrenia. Total Positive and Negative Symptoms Scale (PANSS) score &lt; or = 70 at screening and baseline. Exclusion criteria: Psychiatric diagnosis other than schizophrenia as assessed by the modified Mini International Neuropsychiatric Interview (MINI) and considered by the investigator to be the primary psychiatric diagnosis. History or presence of clinically significant cardiovascular, endocrine, hepatic, renal or other medical disease that might be detrimental to the subject or confound the study. History of any suicide attempt within 3 years of day 1 or significant immediate risk of violence or suicidality.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>